Predictors for early mortality and arrhythmic events in patients with cardiac resynchronization therapy with defibrillator: A two center cohort study by Gunten, Simon von et al.
Address for correspondence: Prof. Beat Schaer, MD, Department of Cardiology, Petersgraben 4, CH 4031 Basel, Switzerland, 
tel: +41 61 328 62 22, fax: +41 61 265 45 80, e-mail: beat.schaer@usb.ch
Received: 27.02.2018 Accepted: 13.10.2018
711www.cardiologyjournal.org
CLINICAL CARDIOLOGY
Cardiology Journal 
2019, Vol. 26, No. 6, 711–716
DOI: 10.5603/CJ.a2018.0144 
Copyright © 2019 Via Medica
ISSN 1897–5593ORIGINAL ARTICLE
Predictors for early mortality and arrhythmic 
events in patients with cardiac  
resynchronization therapy with defibrillator:  
A two center cohort study
Simon von Gunten1, Dominic A. Theuns2, Michael Kühne1, Tobias Reichlin1,  
Christian Sticherling1, Beat Schaer1
1Department of Cardiology, University Hospital, Basel, Switzerland 
2Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands
Abstract
Background: Guidelines of heart failure therapy include cardiac resynchronization as standard of 
care in patients with severely depressed left ventricular function and wide QRS complex. It has been 
shown that patients benefit regarding mortality and morbidity. However, early mortality precludes long-
term benefits from the device. The aim of the study was to identify predictors for early occurrence of 
both death and first-ever implantable cardioverter-defibrillator (ICD) therapy using a large combined 
database of patients with cardiac resynchronization therapy with defibrillator (CRT-D).
Methods: From two registries (tertiary care centers) 904 patients were identified, no single patient was 
excluded. Early death was defined as death occurring within the 3 years after implantation whereas 
early ICD therapy as such occurring within the first year. 33 baseline parameters were compared using 
uni- and multivariate analysis with the Cox model and binary logistic regression.
Results: The population was predominantly male (77%), with mean age of 63 ± 11 years and pri-
mary prevention indication in 80%. Mean follow-up was 55 ± 38 months. 256 (28%) patients had 
ICD therapies whereof the first-ever event occurred early in 52%. 270 (30%) patients died after 41 ±  
± 31 months, mostly from advancing heart failure (41%), 141 (52%) patients of them early. Independent 
predictors for early ICD therapy were secondary prevention and renal failure. Independent predictors for 
early mortality were a history of percutaneous coronary intervention and of peripheral vascular disease.
Conclusions: Predictors for early mortality after CRT-D implantation were a history of percutaneous 
coronary intervention and peripheral vascular disease, present in only a minority of patients, thus limit-
ing their use in clinical practice. (Cardiol J 2019; 26, 6: 711–716)
Key words: cardiac resynchronization therapy, implantable cardioverter-defibrillator, 
mortality, predictive model, decision making
Introduction
Implantation of a cardiac resynchronization 
therapy (CRT) device is standard of care in the 
therapy of heart failure patients with severely de-
pressed left ventricular function and a wide QRS 
complex. Several randomized controlled trials 
have shown remarkable benefits of CRT regard-
ing mortality and morbidity in combination with 
an implantable cardioverter-defibrillator (ICD) but 
also with a stand-alone pacemaker [1, 2]. Many pa-
tients present with left ventricular ejection fraction 
(LVEF) below 35%, and thus are implanted with 
a CRT defibrillator (CRT-D). However, no strong 
evidence suggests that CRT-D must be used in all 
patients that are CRT candidates [3]. A relevant 
number of patients have severe comorbidities and 
die early after implant. Therefore, they might not 
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be in need of the ICD component of a CRT-D [4, 5]. 
Identification of such patients is considered im-
portant, as death as the competing event obviously 
precludes potential long-term benefit from the ICD 
component of CRT. Data regarding first-ever ICD 
therapy are conflicting; studies have shown both 
linear and asymptotic event curves [6–8]. The 
aim of this study was to determine independent 
predictors for early occurrence of both death and 
first-ever ICD therapy. If meaningful and/or highly 
prevalent predictors were identified, they could 
help in decision making for CRT-D or for CRT-
-pacemaker (CRT-P).
Methods
The study population consisted of all consecu-
tive patients in whom a CRT-D was implanted at 
the Erasmus Medical Center, Rotterdam, the 
Netherlands or at the University of Basel Hospital, 
Switzerland. At the sites, patients are entered into 
separate registries that were started in Rotterdam 
in November 1999 (n = 608 patients) and in Basel 
in February 2000 (n = 296 patients). Last access to 
the database was July 2015 for Rotterdam patients 
and May 2015 for Basel patients. Data merging 
was performed in August 2015. No patients were 
excluded, leading to a total amount of 904 patients. 
Deaths were classified as being due to pro-
gressive heart failure, clearly non-cardiac causes, 
sudden (i.e. a sudden death without post mortem 
analysis of the CRT-D and/or necropsy) or ar-
rhythmic (i.e. the device could be interrogated 
showing either ventricular fibrillation that could 
not have been terminated by all shocks or sinus 
rhythm after successful shocks with subsequent 
electromechanical dissociation).
Patient and device characteristics are re-
corded prospectively at baseline, including 33 
parameters such as demographic and cardiovas-
cular items, comorbidities, drugs and laboratory 
values. Missing values of LVEF of 66 patients 
from Rotterdam were imputed as well as 5 miss-
ing values of blood urea nitrogen levels, and 
2 values of QRS width and sodium, respectively, 
using the median of each parameter [9]. Renal 
failure was defined as  glomerular filtration 
rate (GFR) < 60 mL/min/1.73 m2. Appropriate 
ICD therapy are considered in the ventricular 
tachycardia (VT) zone of the ICD (tachycardia of 
180–220/min, primarily terminated by antitachy-
cardia pacing [ATP] or cardioversion shock if ATP 
failed) and in the ventricular fibrillation (VF) 
zone (tachycardias > 220/min terminated by ATP 
during charging or by cardioversion shock). True 
ventricular fibrillation terminated by defibrilla-
tion was studied separately. In cases where ATP 
accelerated the VT into the VF zone, the initial 
VT was considered as the event of interest. The 
first-ever ICD therapy was defined as early when 
occurring within 12 months after implantation 
(median time of first-ever ICD therapy). Death 
was defined as early when occurring within 
3 years after implantation (median time of death). 
All 33 baseline parameters were compared in 
univariate analysis for both events. 
Statistical analysis
Continuous variables are presented as mean 
± standard deviation or median with interquartile 
range and categorical variables as numbers and 
percentages. To determine the prognostic impact 
of significant variables, univariate Cox regression 
and binary logistic regression were used to com-
pute hazard ratios (respectively odds ratios [ORs]) 
and 95% confidence intervals (CIs). All variables 
predicting death or ICD therapies significantly with 
a p value of ≤ 0.1 in the univariate model were 
entered in a multivariate model using the forward 
stepwise method. Statistical analyses were per-
formed with the use of IBM SPSS Statistics for 
Windows, version 23.0 (SPSS Inc. Chicago, IL).
The study is a retrospective merged analysis 
of data collected prospectively in both centers.
Results
Baseline characteristics and follow-up
A merged population of 904 patients was pre-
dominantly male (77%), had a mean age of 63 ± 11 
years at implant and a primary prevention indica-
tion in 80%. Mean follow-up was 55 ± 38 months. 
Table 1 depicts all relevant baseline characteristics 
in detail. Figure 1 shows a flow chart of patients 
included in the study, mortality rate and mode of 
death, the arrhythmias treated by the ICD, and 
their separation into early or non-early events.
ICD therapies
During follow-up, 256 (28%) patients had ICD 
therapies. The first-ever event occurred early in 134 
(52%) patients. In 2/3 ICD, therapy was delivered in 
the VT zone (82% of them occurring early), in 1/3, 
in the VF zone of the ICD (77% of them occurring 
early). Independent predictors for early ICD therapy 
were secondary prevention (OR 3.21, 1.84–5.56, 
0.01) and renal failure (OR 2.08, 1.24–3.50, 0.01). 
More detailed data is presented in Tables 2 and 3. 
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Independent predictors for VT as compared to fast 
VT/VF were beta-blocker therapy (OR 1.77, 1.09– 
–2.86, 0.02) and increasing hemoglobin level (hazard 
ratio per 1 g/L 1.02, 1.01–1.04, 0.01).
Mortality
Overall, 270 (30%) patients died after a mean 
41 ± 31 months, mostly from advancing heart 
failure (41%) or non-cardiac causes (18%). Of note, 
the cause of death (not the time of death) was not 
recorded in the dataset in 33%. 141 (52%) patients 
had died within the first 3 years and thus early. 
Independent predictors for early mortality were 
a history of percutaneous coronary intervention 
(PCI) (OR 2.01, 1.10–3.66, 0.02) and peripheral 
vascular disease (PVD) (OR 2.91, 1.08–7.87, 0.04). 
However, only 24% of patients had a history of 
PCI and 7% of PVD. A more detailed overview is 
shown in Table 4.
Discussion
During a mean follow-up of more than 5.5 
years, only 28% of these CRT-D patients had ap-
propriate ICD therapies. The first-ever event oc-
curred early in 52%. A third of them were delivered 
for potentially life-threatening arrhythmias. This 
rate is slightly lower than the mortality of these 
severely sick patients (50% renal failure, 66% in 
the New York Heart Association [NYHA] class III 
or ambulatory class IV). With the inclusion of 33 
parameters to study early ICD therapy and early 
mortality, it was determined that secondary pre-
vention and renal failure were predictors for early 
ICD therapy and history of PCI and PVD for early 
mortality. 
It would be both scientifically intriguing and 
clinically helpful to identify those patients who 
either die early after ICD implantation (and in 
whom CRT-D implantation can be questioned 
and CRT-P offered) or those who never experi-
ence ICD therapies. It is thus not surprising 
that several studies have been undertaken with 
the focus of early mortality [4, 6, 10, 11]. In the 
present study only history of PCI and PVD were 
identified as predictors for early mortality, i.e. at 
3 years. However, the clinical application of them 
has to be questioned, as they were present in only 
24% and 7% of patients, respectively. In addition, 
a sub-analysis from MADIT-CRT showed that 
a history of PCI, independent of frequency or tim-
ing before enrolment, did not influence mortality 
[12]. Finally, there is no intuitive explanation for 
these two identified predictors and, due to the 
low number of patients with these comorbidities, 
a type I error especially for PVD cannot be ex-
cluded. In summary, this study failed to fulfil the 
particular aim of predicting early mortality in 
a clinically applicable way.
Table 1. Baseline characteristics of  
the 904 patients.
Male gender 700 (77%)
Age at implant [years] 63 ± 11
Weight [kg] 82 ± 16
Body mass index 27 ± 5
Systolic BP [mmHg] 112 ± 19
Ejection fraction [%] 25 ± 7
QRS width [ms] 163 ± 29
Primary prevention 720 (80%)
Sinus rhythm 793 (88%)
NYHA I class 8 (1%)
NYHA II class 297 (33%)
NYHA III class 571 (63%)
Ambulatory NYHA IV class 28 (3%)
Clearance [mL/min/1.73 m2] 64 ± 25
Renal failure  
(GFR < 60 mL/min/1.73 m2)
434 (48%)
Ischemic cardiomyopathy 451 (50%)
Myocardial infarction 371 (41%)
PCI 218 (24%)
CABG 191 (21%)
Diabetes mellitus 224 (25%)
Stroke 112 (12%)
COPD 107 (12%)
Cancer 70 (8%)
PVD 62 (7%)
Drug therapy:
Diuretics 758 (84%)
ACE-inhibitors 751 (83%)
Beta-blockers 736 (81%)
Statins 508 (56%)
Aldosterone antagonists 416 (46%)
Angiotensin receptor blockers 216 (24%)
Amiodarone 202 (22%)
Digoxin 189 (21%)
Allopurinol 71 (8%)
Sodium [mmol/L] 139 ± 4
Hemoglobin [g/L] 134 ± 18
Blood urea nitrogen [mmol/L] 10 ± 6
ACE — angiotensin converting enzyme; BP — blood pressure; 
CABG — coronary artery bypass grafting; COPD — chronic  
obstructive pulmonary disease; GFR — glomerular filtration rate; 
NYHA — New York Heart Association; PCI — percutaneous  
coronary intervention; PVD — peripheral vascular disease
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In CRT-D patients, no similar data are available 
to date. In a large ICD only cohort study with a vali-
dation cohort (total patient number 2700, 75% pri-
mary prevention) [10], four factors predicted mor-
tality at 1 year. They were PVD, age > 70 years, 
LVEF < 20% and creatinine > 176 mmol/L. Pa-
tients with only one factor had a mortality of 4% as 
compared to 18% in those with four factors. Results 
were confirmed in a population of 800 patients 
(100% primary prevention, 28% CRT-D) [4]. Age 
(here: > 75 years), impaired renal function (here: 
GFR < 30 mL/min/1.73 m2), QRS width > 120 ms, 
and atrial fibrillation were the four predictors. 
Mortality at 1 year was 2.5% in patients with 0 or 
1 risk factors, but 46% in those with all four fac-
tors present. However, both papers do not discuss 
the fact that only 2% of patients were labelled as 
very high-risk patients, which renders the useful-
ness of these impressive results less applicable 
in daily life.
In a study of 225 octogenarians, LVEF < 20% 
and lack of beta-blocker therapy were the only two 
Figure 1. Flow chart of patients and cardiac events; VT — ventricular tachycardia (> 180/min); fast VT — fast ventricular 
tachycardia (> 220/min); VF — true ventricular fibrillation.
904 patients:
296 from Basel
608 from Rotterdam
634 alive and in study 12/2015
270 died up to 12/2015
 110 heart failure
 49 non-cardiac
 14 arrhythmia
 9 sudden death
 88 unknown
83 lost to follow-up
648 
event-free patients
256 
cardiac events
168 VT 
as rst event
75 fast VT 
as rst event
13 VF 
as rst event
34 early 41 late 8 early 5 late92 early 76 late
Table 2. Univariable and multivariable analysis for occurrence of first-ever implantable cardioverter-
defibrillator therapy without temporal discrimination (only significant parameters are shown, hazard 
ratio < 1 = no cardiac event, hazard ratio > 1 = cardiac event).
Univariable analysis Multivariable analysis
HR 95% CI P HR 95% CI P
Secondary prevention 1.596 1.232–2.068 0.000 1.534 1.183–1.990 0.001
Renal failure 1.468 1.142–1.888 0.003 1.408 1.093–1.814 0.008
Amiodarone therapy 1.423 1.075–1.883 0.014 –
Clearance [mL/min/1.73 m2] 0.993 0.987–0.999 0.014 –
Age at implant [year] 1.015 1.005–1.026 0.004 –
Blood urea nitrogen [mmol/L] 1.022 0.998–1.046 0.074 –
CI — confidence interval; HR — hazard ratio
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Table 3. Uni- and multivariable analyses for occurrence of first-ever implantable cardioverter-defibrillator 
therapy with discrimination between early and late events (only significant parameters are shown, 
odds ratio < 1 = early [≤ 12 months], odds ratio > 1 = late [> 12 months]).
Univariable analysis Multivariable analysis
OR 95% CI P OR 95% CI P
Secondary prevention 0.302 0.175–0.521 0.000 0.312 0.180–0.543 0.000
Renal failure 0.457 0.277–0.754 0.002 0.480 0.286–0.807 0.006
Amiodarone therapy 0.623 0.355–1.092 0.098 –
ARB therapy 1.671 0.935–2.987 0.083 –
Age at implant [year] 0.969 0.948–0.990 0.005 –
Weight [kg] 1.018 1.001–1.034 0.036 –
Blood urea nitrogen [mmol/L] 0.951 0.906–0.998 0.040 –
Clearance [mL/min/1.73 m2] 1.016 1.005–1.027 0.006 –
Hemoglobin [g/L] 1.015 1.002–1.029 0.029 –
ARB — angiotensin receptor blocker; CI — confidence interval; OR — odds ratio
Table 4. Uni- and multivariable analyses for occurrence of early death (only significant parameters are 
shown, odds ratio < 1 = early [≤ 36 months], odds ratio > 1 = late [> 36 months]).
Univariable analysis Multivariable analysis
OR 95% CI P OR 95% CI P
Ischemic cardiomyopathy 0.651 0.396-1.071 0.091 –
PCI 0.556 0.318-0.973 0.040 0.498 0.273-0.908 0.023
Diabetes mellitus 0.639 0.376–1.086 0.098 –
PVD 0.313 0.121–0.811 0.017 0.344 0.127–0.930 0.035
Renal failure 0.440 0.265–0.729 0.001 –
Digoxin therapy 0.600 0.354–1.018 0.058 –
Weight [kg] 1.019 1.003–1.035 0.019 –
Body mass index [Unit] 1.051 1.000–1.104 0.050 –
Systolic BP [mmHg] 1.012 0.999–1.024 0.073 1.015 1.002–1.029 0.025
Blood urea nitrogen [mmol/L] 0.963 0.926–1.000 0.050 –
Clearance [mL/min/1.73 m2] 1.018 1.007–1.029 0.001 1.020 1.009–1.031 0.001
Hemoglobin [g/L] 1.013 0.999–1.026 0.060 –
BP — blood pressure; CI — confidence interval; OR — odds ratio; PCI — percutaneous coronary intervention; PVD — peripheral vascular disease
predictors of mortality at 1 year. Mortality of pa-
tients with LVEF < 20% was threefold compared to 
those with LVEF > 20%, but the patient number at 
risk are not mentioned, thus severely limiting this 
statement. Finally, the Italian IRIDE registry [6] 
reported their results on 600 patients with primary 
prevention (43% CRT-D). They showed a linear 
increase of mortality to 24% at 4 years, which is 
similar to the present results. This is surprising, 
given the much higher disease burden in the cur-
rent study (48% renal failure and 71% NYHA class 
III/IV vs. 11% and 38%, respectively). In addition, 
even though ICD programing is comparable, the 
rate of ICD therapies was as high as 50% after 
5 years, as opposed to 28% in the study herein.
Other factors are also not especially analyzed in 
this paper, as e.g. metabolic syndrome with or without 
obesity, were not shown to influence mortality [13].
To identify predictors of ICD therapy, early or 
rather late after implantation, is less useful in daily 
life. This is because a) there are data [7] show-
ing that a substantial proportion of patients have 
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their first ICD therapy after 5 years and b) espe-
cially in secondary prevention guidelines regarding 
continuation of ICD treatment even in patients 
without ICD therapy for many years are clear-cut. 
Nevertheless, this issue has been investigated 
herein. In the present CRT-D population, only 
two predictors could be identified (after analysing 
33 parameters) for early ICD therapy, secondary 
prevention (which is commonly known) and re-
nal failure. A Dutch cohort study [8] did not find 
a predictor using eight parameters. Identifying pre-
dictors that somehow “protect” patients from early 
or late ICD therapy seems alluring at first glance, 
as one could argue that such a patient might not 
be in need of the ICD part of CRT. Further studies 
especially in patients with dilated cardiomyopathy 
are needed that include parameters not used in the 
present dataset such as a true left bundle branch 
block as compared to other forms of QRS widen-
ing or late gadolinium enhancement as seen on 
magnetic resonance imaging.
Limitations of the study
This study has all the limitations of a retro-
spective database study. There was no “control 
group” with patients with only CRT-P, who might 
have had other predictors for early death other 
than CRT-D patients. Some data had to be imputed. 
Finally, about 10% were lost to follow-up, and in 
about the same percentage, the mode of death 
was unknown. This does, however, not influence 
prediction of early mortality, as the analysis was 
performed regarding all-cause mortality.
Conclusions
Predictors for early mortality after CRT-D im-
plantation were a history of PCI and PVD, however 
present in only a minority of patients. A survey of 
the available literature suggests that it is difficult 
to predict early mortality, albeit this would impact 
on those patients with a high chance of dying and 
have no benefit from the ICD part of CRT.
Conflict of interest: Simon von Gunten and Tobias 
Reichlin: none declared; Dominic A. Theuns: Bio-
tronik: research funding, Boston Scientific: research 
funding, consultant; Michael Kühne: Medtronic: 
proctor; Christian Sticherling: Biotronik: speaker 
bureau, consultant, investigator, research funding; 
Boston Scientific: investigator; Medtronic: investi-
gator, advisory board; Microport: speaker bureau, 
consultant; Beat Schaer: Medtronic: speaker bu-
reau; Microport: speaker bureau
References
1. Cleland JGF, Daubert JC, Erdmann E, et al. The effect of cardiac 
resynchronization on morbidity and mortality in heart failure. 
N Engl J Med. 2005; 352(15): 1539–1549, doi:  10.1056/NEJ-
Moa050496, indexed in Pubmed: 15753115.
2. Tang ASL, Wells GA, Talajic M, et al. Cardiac-resynchronization 
therapy for mild-to-moderate heart failure. N Engl J Med. 2010; 
363(25): 2385–2395, doi:  10.1056/NEJMoa1009540, indexed in 
Pubmed: 21073365.
3. Daubert JC, Martins R, Leclercq C, et al. Why we have to 
use cardiac resynchronization therapy-pacemaker more. 
Card Electrophysiol Clin. 2015; 7(4): 709–720, doi:  10.1016/j.
ccep.2015.08.016, indexed in Pubmed: 26596813.
4. Kraaier K, Scholten MF, Tijssen JGP, et al. Early mortality in 
prophylactic implantable cardioverter-defibrillator recipients: 
development and validation of a clinical risk score. Europace. 
2014; 16(1): 40–46, doi:  10.1093/europace/eut223, indexed in 
Pubmed: 23918791.
5. Theuns DA, Schaer BA, Soliman OII, et al. The prognosis of 
implantable defibrillator patients treated with cardiac resynchro-
nization therapy: comorbidity burden as predictor of mortality. 
Europace. 2011; 13(1): 62–69, doi:  10.1093/europace/euq328, 
indexed in Pubmed: 20833692.
6. Proclemer A, Muser D, Campana A, et al. Indication to cardioverter-
defibrillator therapy and outcome in real world primary prevention. 
Data from the IRIDE [Italian registry of prophylactic implanta-
tion of defibrillators] study. Int J Cardiol. 2013; 168(2): 1416–1421, 
doi: 10.1016/j.ijcard.2012.12.042, indexed in Pubmed: 23287697.
7. Reichlin T, Kühne M, Sticherling C, et al. Characterization and 
financial impact of implantable cardioverter-defibrillator pa-
tients without interventions 5 years after implantation. QJM. 
2011; 104(10): 849–857, doi: 10.1093/qjmed/hcr081, indexed in 
Pubmed: 21624895.
8. Ypenburg C, van Erven L, Bleeker GB, et al. Benefit of com-
bined resynchronization and defibrillator therapy in heart failure 
patients with and without ventricular arrhythmias. J Am Coll 
Cardiol. 2006; 48(3): 464–470, doi:  10.1016/j.jacc.2006.04.072, 
indexed in Pubmed: 16875970.
9. Rubin DB, Schenker N. Multiple imputation in health-care data-
bases: an overview and some applications. Stat Med. 1991; 10(4): 
585–598, indexed in Pubmed: 2057657.
10. Kramer DB, Friedman PA, Kallinen LM, et al. Development 
and validation of a risk score to predict early mortality in recipi-
ents of implantable cardioverter-defibrillators. Heart Rhythm. 
2012; 9(1): 42–46, doi: 10.1016/j.hrthm.2011.08.031, indexed in 
Pubmed: 21893137.
11. Ertel D, Phatak K, Makati K, et al. Predictors of early mortality in 
patients age 80 and older receiving implantable defibrillators. Pac-
ing Clin Electrophysiol. 2010; 33(8): 981–987, doi: 10.1111/j.1540-
8159.2010.02729.x, indexed in Pubmed: 20230459.
12. Husaini M, Biton Y, Stair B, et al. Effectiveness of cardiac re-
synchronization therapy by the frequency of revascularization 
procedures in ischemic cardiomyopathy patients. Cardiol J. 
2016; 23(4): 437–445, doi:  10.5603/CJ.a2016.0032, indexed in 
Pubmed: 27320956.
13. Szepietowska B, McNitt S, Polonsky B, et al. Metabolic syn-
drome is associated with different clinical outcome after car-
diac resynchronization therapy in patients with ischemic and 
non-ischemic cardiomyopathy. Cardiol J. 2016; 23(3): 344–351, 
doi: 10.5603/CJ.a2016.0017, indexed in Pubmed: 27064797.
